Please assess the completion status of the following clinical trial:

Trial Title: Safety,PK/PD, Food Effect Study of Orally Administered HM71224 in Healthy Adult Male Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 11.0

Eligibility Criteria:
Inclusion Criteria:~1. Gender : male~2. Age : 18-65 years, inclusive~3. BMI : 18.5 - 30.0 kg/m2~4. Ability and willingness to abstain from alcohol, methylxanthine-containing beverages or food (coffee, tea, cola, chocolate, energy drinks), and grapefruit (juice) from 48 h prior to entry in the clinical research center until discharge~5. Medical history without major pathology~6. Normal resting supine blood pressures and pulse rate, showing no clinically relevant deviations as judged by the MI~7. Computerized (12-lead) electrocardiogram (ECG) recording without signs of clinically relevant pathology or showing no clinically relevant deviations as judged by the MI~8. Willingness to use adequate contraception from the time of dosing until 90 days after the follow-up visit~9. All values for hematology and for clinical chemistry tests of blood and urine within the normal range or showing no clinically relevant deviations as judged by the MI~10. Willingness to sign the written Informed Consent Form (ICF)~Exclusion Criteria:~1. Previous participation in the current study~2. Evidence of clinically relevant pathology~3. Mental handicap~4. History of relevant drug and/or food allergies~5. Regular/routine treatment with non-topical medications within 30 days prior to entry into the clinical research center~6. Use of tobacco products within 60 days prior to drug administration~7. History of alcohol abuse or drug addiction (including soft drugs like cannabis products)~8. Use of concomitant medication, except for acetaminophen (paracetamol), which is allowed up to 3 days before entry into the clinical research center. Multivitamins and vitamin C are allowed up to 7 days before entry into the clinical research center. All other medication (including over the counter medication, health supplements, and herbal remedies such as St. John's Wort extract) must have been stopped at least 14 days prior to entry into the clinical research center. The use of a limited amount of acetaminophen during the study is permitted.~9. Participation in a drug study within 60 days prior to drug administration. Participation in more than 3 other drug studies in the 10 months preceding the start of this study (this is the first administration of study drug).~10. Donation of more than 50 mL of blood within 60 days prior to drug administration. Donation of more than 1.5 liters of blood in the 10 months preceding the start of this study (this is the first administration of study drug).~11. Positive drug screen (opiates, methadone, cocaine, amphetamines, cannabinoids, barbiturates, benzodiazepines, and alcohol)~12. Intake of more than 24 units of alcohol per week (one unit of alcohol equals approximately 250 mL of beer, 100 mL of wine or 35 mL of spirits)~13. Positive screen on Hepatitis B Surface Antigen (HBsAg), anti-Hepatitis C Virus (HCV) or anti-Human Immunodeficiency Virus (HIV) 1/2~14. Illness within 5 days prior to the first drug administration~15. Non-willingness to consume the FDA breakfast (Part B only)

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Treatment A Period 2 (Type: EXPERIMENTAL): 40mg HM71224 single dose
- Treatment B Period1 (Type: EXPERIMENTAL): 20mg HM71224 single dose
- Treatment A Period1 (Type: EXPERIMENTAL): 10mg HM71224 single dose
- Treatment B Period2 (Type: EXPERIMENTAL): 80mg HM71224 single dose
- TreatmentA Period3 (Type: EXPERIMENTAL): 160mg HM71224 single dose
- TreatmentB Period3 (Type: EXPERIMENTAL): 200mg HM71224 single dose
- Food effect period1 (Type: EXPERIMENTAL): active 4subjects + placebo 4subjects
- Food effect period2 (Type: EXPERIMENTAL): active 4subjects + placebo 4subjects
- TreatmentC (Type: EXPERIMENTAL): HM71224 Xmg multiple dose for 14days
- TreatmentD (Type: EXPERIMENTAL): HM71224 Ymg 14days multiple dose
- TreatmentE (Type: EXPERIMENTAL): HM71224 Zmg 14days multiple dose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete